Cargando…
Experimental Combined Immunotherapy of Tumours with Major Histocompatibility Complex Class I Downregulation
Combined immunotherapy constitutes a novel, advanced strategy in cancer treatment. In this study, we investigated immunotherapy in the mouse TC-1/A9 model of human papillomavirus type 16 (HPV16)-associated tumors characterized by major histocompatibility complex class I (MHC-I) downregulation. We fo...
Autores principales: | Grzelak, Adrianna, Polakova, Ingrid, Smahelova, Jana, Vackova, Julie, Pekarcikova, Lucie, Tachezy, Ruth, Smahel, Michal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274939/ https://www.ncbi.nlm.nih.gov/pubmed/30469401 http://dx.doi.org/10.3390/ijms19113693 |
Ejemplares similares
-
Distinct Responsiveness of Tumor-Associated Macrophages to Immunotherapy of Tumors with Different Mechanisms of Major Histocompatibility Complex Class I Downregulation
por: Piatakova, Adrianna, et al.
Publicado: (2021) -
Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade
por: Vackova, Julie, et al.
Publicado: (2020) -
CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
por: Vackova, Julie, et al.
Publicado: (2021) -
Aspartate β-hydroxylase as a target for cancer therapy
por: Kanwal, Madiha, et al.
Publicado: (2020) -
Implementation of Mass Cytometry for Immunoprofiling of Patients with Solid Tumors
por: Poláková, Ingrid, et al.
Publicado: (2019)